Avecho Advances Phase III Insomnia Trial After Positive Interim Review
Melbourne-based Avecho Biotechnology will continue its pivotal Phase III insomnia trial after an independent Data Monitoring Board confirmed the study met key interim criteria. The review of 244 participants showed no serious adverse events, clearing the path for the company to enroll the full cohort of 519 patients.




















